Suppression of high lipid diet induced by atherosclerosis sarpogrelate
- PMID: 22348587
- PMCID: PMC3823433
- DOI: 10.1111/j.1582-4934.2012.01554.x
Suppression of high lipid diet induced by atherosclerosis sarpogrelate
Abstract
Sarpogrelate (SP), a serotonin (5-HT2A) receptor antagonist, is used as an anti-platelet agent for the treatment of some vascular diseases. SP has been reported to inhibit 5-HT induced coronary artery spasm, increase in intracellular calcium and smooth muscle cells proliferation. This study was undertaken to test that SP suppresses the development of atherosclerosis due to high cholesterol diet (HCD) by decreasing blood viscosity and oxidative stress. For this purpose, 29 rabbits were divided into four groups: control group (normal diet); normal diet group with SP at the dose of 5 mg/kg/day; HCD group fed 1% cholesterol; and HCD group with SP at the dose of 5 mg/kg/day. After 90 days of the experiment, blood samples were collected and the animals were killed; the thoracic aorta was stained by the Oil Red O staining method. The results indicate that plasma levels of cholesterol, triglycerides and malondialdehyde were increased in rabbits fed HCD. Plasma viscosity and whole blood viscosity were also higher in the HCD group than that in normal diet group. Treatment with SP prevented these alterations induced by HCD whereas this agent had no significant effect in rabbits fed normal diet. Morphological examination of the aorta revealed that SP treatment prevented the formation of foam cells and atherosclerotic plaque. It is suggested that the beneficial effects of SP in atherosclerosis may be due to actions on blood viscosity, lipid levels and oxidative stress.
© 2012 The Authors Journal of Cellular and Molecular Medicine © 2012 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd.
Figures






Similar articles
-
The changes in serum and whole blood rheological properties of rabbits during the progression of atherosclerosis.Pak J Pharm Sci. 2016 May;29(3 Suppl):1053-7. Pak J Pharm Sci. 2016. PMID: 27383483
-
Dihydrotestosterone suppresses foam cell formation and attenuates atherosclerosis development.Endocrinology. 2010 Jul;151(7):3307-16. doi: 10.1210/en.2009-1268. Epub 2010 Apr 28. Endocrinology. 2010. PMID: 20427482
-
Sarpogrelate HCl, a selective 5-HT2A antagonist, retards the progression of atherosclerosis through a novel mechanism.Atherosclerosis. 2003 May;168(1):23-31. doi: 10.1016/s0021-9150(03)00054-6. Atherosclerosis. 2003. PMID: 12732383
-
Antioxidant and anti-inflammatory effects of flavocoxid in high-cholesterol-fed rabbits.Naunyn Schmiedebergs Arch Pharmacol. 2015 Dec;388(12):1333-44. doi: 10.1007/s00210-015-1168-4. Epub 2015 Sep 4. Naunyn Schmiedebergs Arch Pharmacol. 2015. PMID: 26341793
-
[The anti-atherosclerotic effect and mechanism of itaconate].Zhonghua Xin Xue Guan Bing Za Zhi. 2024 Jun 24;52(6):708-712. doi: 10.3760/cma.j.cn112148-20231008-00245. Zhonghua Xin Xue Guan Bing Za Zhi. 2024. PMID: 38880754 Review. Chinese.
Cited by
-
Blocking 5-HT2 receptor restores cardiovascular disorders in type 1 experimental diabetes.Sci Rep. 2016 Sep 23;6:33979. doi: 10.1038/srep33979. Sci Rep. 2016. PMID: 27659784 Free PMC article.
-
Sarpogrelate and rosuvastatin synergistically ameliorate aortic damage induced by hyperlipidemia in apolipoprotein E-deficient mice.Exp Ther Med. 2020 Dec;20(6):170. doi: 10.3892/etm.2020.9300. Epub 2020 Oct 9. Exp Ther Med. 2020. PMID: 33093907 Free PMC article.
-
Efficacy and Safety of Sarpogrelate on Symptom Improvement in Patients with Peripheral Arterial Disease (PAD) and/or Being at Risk of PAD: A Single Arm, Multi-Centered, Open-Label Trial.Curr Vasc Pharmacol. 2025;23(1):45-56. doi: 10.2174/0115701611285172241015074050. Curr Vasc Pharmacol. 2025. PMID: 39440727 Clinical Trial.
-
Pravastatin and Sarpogrelate Synergistically Ameliorate Atherosclerosis in LDLr-Knockout Mice.PLoS One. 2016 Mar 7;11(3):e0150791. doi: 10.1371/journal.pone.0150791. eCollection 2016. PLoS One. 2016. PMID: 26950217 Free PMC article.
-
Prevention of diabetes-induced cardiovascular complications upon treatment with antioxidants.Heart Fail Rev. 2014 Jan;19(1):113-21. doi: 10.1007/s10741-013-9379-6. Heart Fail Rev. 2014. PMID: 23436032 Review.
References
-
- Saini HK, Takeda N, Goyal RK, et al. Therapeutic potentials of sarpogrelate in cardiovascular disease. Cardiovasc Drug Rev. 2004;22:27–54. - PubMed
-
- Sharma SK, Zahradka P, Chapman D, et al. Inhibition of serotonin-induced vascular smooth muscle cell proliferation by sarpogrelate. J Pharmacol Exp Ther. 1999;290:475–81. - PubMed
-
- Nagatomo T, Rashid M, Muntasir HA, et al. Functions of 5-HT2A receptor and its antagonists in the cardiovascular system. Pharmacol Ther. 2004;104:59–81. - PubMed
-
- Sanganalmath SK, Barta J, Takeda N, et al. Antiplatelet therapy mitigates cardiac remodeling and dysfunction in congestive heart failure due to myoscardial infarction. Can J Physiol Pharmacol. 2008;86:180–9. - PubMed
-
- Nishihira K, Yamashita A, Tanaka N, et al. Inhibition of 5-hydroxytryptamine receptor prevents occlusive thrombus formation on neointima of the rabbit femoral artery. J Thromb Haemost. 2006;4:247–55. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical